Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

The research service primarily encompasses comprehensive analyses of key emerging therapies across AD and PD.The service includes treatment overviews, emerging therapeutic platforms, IP and funding analysis, and emerging innovation profiles across Alzheimer's and Parkinson's diseases. Furthermore, the research service features the impact of key technology drivers and restraints for the global AD and PD therapeutic industry. The research services also provides an summary of collaborative trends, regional adoption potential, emerging therapeutic platforms and novel growth opportunities across AD and PD.

Table of Contents

1.0 Executive Summary1.1 Research Scope1.2 Research Methodology1.2 Research Methodology (Continued)1.3 Key Findings2.0 Overview of Neurodegenerative Disorders2.1 Alzheimer’s and Parkinson’s Diseases Are Leading Causes of Neurodegenerative Disorders2.2 Disease-modifying Therapies Likely to Lead Emerging Landscape for AD and PD Management2.3 Healthcare Burden for AD and PD Likely to Increase in the Future3.0 Impact Analysis and Assessment3.1 Summary of Key Technology Drivers and Restraints3.2 Technological Advancements Likely to Fuel New Therapeutics for Neurodegenerative Disorders3.3 Clinical Trial Advancements of Novel Neurological Therapies Limited by High Failure Rates4.0 Alzheimer’s Disease4.1 Cholinesterase Inhibitors Lead Existing Treatment Platforms for Alzheimer’s Disease4.2 Disease-modifying Agents Likely to Have High Impact across AD Patients4.3 US Leads the Patent Landscape for Novel AD Therapies4.4 Denali Therapeutics Leads the Global Venture Landscape for AD Treatment4.5 Amyloid Therapies Lead the Emerging AD Treatment Landscape4.6 Clinical Pipeline Overview for AD4.7 Small Molecule RIP1 Inhibitor for Treating AD4.8 Novel Second Generation Tau-aggregation Inhibitor for AD Management4.9 Immunomodulatory Strategies for Clinical Management of AD4.10 Targeting Amyloid Aggregates for Clinical Management of Neurodegeneration5.0 Parkinson’s Disease5.1 Levadopa Leads the Existing PD Treatment Landscape5.2 Biologics Pipeline Likely to Garner Increased Focus across the Emerging PD Treatment Landscape5.3 Emerging Disease-modifying Small Molecules Likely to Lead PD Management 5.4 US Leads the Patent Landscape for Novel PD Therapies5.5 Significant NIH and Venture Funding Indicative of Growing Focus on PD Therapeutics 5.6 Clinical Pipeline Overview for PD5.7 Viral Gene Therapy for PD5.8 Integrated Therapeutic Platform for Neurodegenerative Diseases5.9 Novel Wearable for Tremor Management5.10 Targeted Vaccine Platform for PD6.0 Strategic Insights and Future Perspectives6.1 Overview of the Collaborative Landscape6.2 Developed Economies Likely to Lead Global Adoption Scenario for Neurodegenerative Therapies6.3 New Symptomatic and Disease-Modifying Treatments for AD and PD on the Horizon7.0 Growth Opportunities and Companies to Action7.1 Growth Opportunity 1: Disease-modifying Therapy7.2 Growth Opportunity 2: Immunotherapies7.3 Growth Opportunity 3: Gene Therapies7.4 Strategic Imperatives for Success and Growth 8.0 Appendix8.1 Key Contacts8.1 Key Contacts (Continued)Legal Disclaimer9.0 The Frost & Sullivan Story9.1 The Frost & Sullivan Story9.2 Value Proposition: Future of Your Company & Career9.3 Global Perspective9.4 Industry Convergence9.5 360º Research Perspective9.6 Implementation Excellence9.7 Our Blue Ocean Strategy

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.